Compare Aurora Cannabis Inc (ACB) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs Morgan Stanley — how do they compare? Aurora Cannabis Inc trades at $2.67 (market cap $165.36M), while Morgan Stanley trades at $218.36 (market cap $350.22B). The key difference: Morgan Stanley is far larger — about 2117.9× Aurora Cannabis Inc's market cap, and Morgan Stanley pays a 1.8% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | MS | |
|---|---|---|
Market Cap | $165.36M | $350.22B |
Sector | Health | Financials |
52-Week High | $6.23 | $227.19 |
52-Week Low | $2.67 | $139.09 |
Enterprise Value | $99.82M | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.
The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.
Morgan Stanley (MS) trades at $222.10, up 3.82% today, near its consensus price target of $225.80. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth, reaching $66.0B in 2025. Technical indicators are bullish, with the current price above key support levels. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive given earnings outperformance and analyst consensus, though risks include volatile cash flows and high debt levels. Upside potential exists if the company maintains its growth trajectory and executes on strategic initiatives like the Anthropic IPO. Investors should monitor interest rate sensitivity and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
